Linkaim.com

Favipiravir searching

Top keyword related from Search Engine of favipiravir

Top URL related to favipiravir

1. Favipiravir - Wikipedia
wikipedia.org

Link: https://en.wikipedia.org/wiki/Favipiravir

Description: WEBFavipiravir, sold under the brand name Avigan among others, [3] is an antiviral medication used to treat influenza in Japan. [4] . It is also being studied to treat a number of other viral infections, including SARS-CoV-2. [4] . Like the experimental antiviral drugs T-1105 and T-1106, it is a pyrazinecarboxamide derivative. [5]
2. Favipiravir: Uses, Interactions, Mechanism of Action | DrugBank …
drugbank.com

Link: https://go.drugbank.com/drugs/DB12466

Description: WEBOct 20, 2016 · Summary. Favipiravir is an antiviral used to manage influenza, and that has the potential to target other viral infections. Generic Name. Favipiravir. DrugBank Accession Number. DB12466. Background.
3. Safety and efficacy of favipiravir in COVID-19 patients with …
biomedcentral.com

Link: https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00124-6

Description: WEBFeb 25, 2024 · Favipiravir administered for ten days to patients with COVID-19 and pneumonia did not improve outcomes compared with placebo. Although this is an underpowered negative study, efficacy results align with other randomized trials. However, in the present study, the non-serious adverse events were more frequent in the …
4. Favipiravir for the treatment of patients with COVID-19: a …
biomedcentral.com

Link: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06164-x

Description: WEBMay 27, 2021 · Favipiravir induces viral clearance by 7 days and contributes to clinical improvement within 14 days. The results indicated that favipiravir has strong possibility for treating COVID-19, especially in patients with mild-to-moderate illness.
5. Clinical antiviral efficacy of favipiravir in early COVID-19 …
biomedcentral.com

Link: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-023-08835-3

Description: WEBJan 15, 2024 · Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries.
6. Is favipiravir useful in treating people with COVID‐19?
cochrane.org

Link: https://www.cochrane.org/CD015219/INFECTN_favipiravir-useful-treating-people-covid-19

Description: WEBWhat is favipiravir? Favipiravir is a medicine that can fight viruses. It is usually taken by mouth. Originally used for treating other viral infections, favipiravir has been suggested as a potential treatment for COVID-19 as it prevents the reproduction of the virus.
7. Benefits of treatment with favipiravir in hospitalized patients for
biomedcentral.com

Link: https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01577-1

Description: WEBPublished: 25 May 2021. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study. Anıl Ucan, Pamir Cerci, Serdar Efe, Hakan Akgun, Ahmet Ozmen, Aysel Yagmuroglu, Muzaffer Bilgin & Deniz Avci. Virology Journal 18, Article number: 102 ( 2021 ) Cite this article. 11k Accesses.
8. Monographs on Favipiravir and on Favipiravir tablets …
who.int

Link: https://cdn.who.int/media/docs/default-source/medicines/imwp-favipiravir-monographs.pdf?sfvrsn=212299e1_13&download=true

Description: WEB3 IMWP MONOGRAPH ON FAVIPIRAVIR AND FAVIPIRAVIR TABLETS (Rev1 - 06 August 2021) 41 Reference Spectrum 42 43 Water: Not more than 0.6% (0.1g, coulometric titration3). 44 Assay: Weigh accurately about 20 mg each of Favipiravir and IMWP RS on Favipiravir 45 (separately determine the water in the Karl-Fisher coulometric titration …
9. Favipiravir In Adults with Moderate to Severe COVID-19: A Phase …
medrxiv.org

Link: https://www.medrxiv.org/content/10.1101/2021.11.08.21265884v1

Description: WEBNov 9, 2021 · Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial | medRxiv. Follow this preprint.
10. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
cdc.gov

Link: https://wwwnc.cdc.gov/eid/article/25/10/19-0607_article

Description: WEBFavipiravir is a broad-spectrum antiviral drug that inhibits viral RNA polymerase, an enzyme recognized as an attractive target because of its critical role in virus replication and high degree of conservation ( 8 ).